CombiMatrix Wins $31.4M Judgment in Lawsuit Against Insurer
CombiMatrix last week said that it has been awarded $31.4 million by the US District Court for the Central District of California in a suit filed against an insurer.
The Mukilteo, Wash.-based manufacturer of DNA arrays said that National Union Fire Ins. Co. of Pittsburgh had refused to defend and indemnify CombiMatrix under its director and officer’s insurance policy with National Union. The money was awarded to CombiMatrix and its former parent company, Acacia Research, but in accordance with an agreement between the two firms, CombiMatrix receives all proceeds from the suit.
CombiMatrix said that it would file a request in the next 30 days to recoup attorneys’ fees.
Spotfire Partners with Integromics on Andalusian Bioinformatics Project
Spotfire, a subsidiary of Tibco Software, said this week that it is working with Integromics of Granada, Spain, to co-develop a genomics software platform for Spain’s Andalusia region.
Integromics is developing the software platform with funding from the governments of Spain and Andalusia. Other partners in the collaboration include the University of Malaga and the University of Cordoba.
Spotfire said that Integromics will use its suite of products to create the platform, which will integrate “complex information and applications” for genomics and transcriptomics.
Financial terms of the agreement were not provided.
Medical Solutions to Distribute Empire Genomics' Genotyping Technology
Medical Solutions will be the exclusive UK distributor and service provider for Empire Genomics’ AccuArray array comparative genomic hybridization genotyping technology under an alliance announced last week.
In addition to distributing the technology, Nottingham, UK-based Medical Solutions said that it would offer genotyping services, including in-house bioinformatics analysis and support, using the technology in its labs. The AccuArray platform also has applications in clinical diagnostics and pharmacogenetic testing, the firms said.
“The diagnostic capability of this assay is of particular interest to those groups in the healthcare community involved in cytogenetic and pre- and post-natal testing,” Tom Weaver, commercial director for Medical Solutions, said in a statement.
He said the AccuArray aCGH could be used to identify genetic aberrations linked with several diseases and conditions, such as cancer, autism, Alzheimer’s, several congenital abnormalities, and Down syndrome.
Terms of the alliance were not disclosed.